Poseida Therapeutics (NASDAQ:PSTX) Given “Market Perform” Rating at William Blair

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “market perform” rating reiterated by William Blair in a research report issued to clients and investors on Tuesday,Benzinga reports.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday.

Poseida Therapeutics Stock Up 228.0 %

NASDAQ PSTX traded up $6.52 on Tuesday, reaching $9.38. The company had a trading volume of 21,172,146 shares, compared to its average volume of 643,383. The company’s fifty day moving average is $2.78 and its 200-day moving average is $2.92. The firm has a market capitalization of $914.17 million, a price-to-earnings ratio of -14.89 and a beta of 0.54. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. Poseida Therapeutics has a 1-year low of $1.87 and a 1-year high of $9.38.

Institutional Trading of Poseida Therapeutics

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after purchasing an additional 473,746 shares during the last quarter. State Street Corp grew its stake in shares of Poseida Therapeutics by 2.3% in the third quarter. State Street Corp now owns 1,710,565 shares of the company’s stock valued at $4,892,000 after buying an additional 38,770 shares in the last quarter. Blair William & Co. IL increased its holdings in Poseida Therapeutics by 14.1% during the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after buying an additional 136,273 shares during the last quarter. Renaissance Technologies LLC raised its position in Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after acquiring an additional 297,500 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Poseida Therapeutics by 89.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after acquiring an additional 391,801 shares during the last quarter. Institutional investors own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.